• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Blood-brain barrier-traversing biologic secures regulatory approval, in Japan.

作者信息

Mullard Asher

出版信息

Nat Rev Drug Discov. 2021 May;20(5):332. doi: 10.1038/d41573-021-00066-y.

DOI:10.1038/d41573-021-00066-y
PMID:33850321
Abstract
摘要

相似文献

1
Blood-brain barrier-traversing biologic secures regulatory approval, in Japan.穿越血脑屏障的生物制剂在日本获得监管批准。
Nat Rev Drug Discov. 2021 May;20(5):332. doi: 10.1038/d41573-021-00066-y.
2
Safety-Related Regulatory Actions and Risk Factors for Anticancer Drugs in Japan.日本抗癌药物的安全相关监管行动及风险因素
Pharmaceut Med. 2019 Feb;33(1):45-52. doi: 10.1007/s40290-018-0260-8.
3
A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making.美国、欧盟和日本基因和细胞治疗药物上市批准十年来的监管决策评估
Cytotherapy. 2018 Jun;20(6):769-778. doi: 10.1016/j.jcyt.2018.03.038. Epub 2018 May 2.
4
Unique characteristics of regulatory approval and pivotal studies of orphan anticancer drugs in Japan.日本孤儿抗癌药物监管审批的独特特点和关键研究。
Invest New Drugs. 2018 Aug;36(4):702-708. doi: 10.1007/s10637-018-0603-z. Epub 2018 Apr 17.
5
Approval Status and Regulatory Actions for Radiopharmaceuticals in the United States and Japan.美国和日本放射性药物的批准状态及监管行动
Ther Innov Regul Sci. 2014 Sep;48(5):635-643. doi: 10.1177/2168479014524406.
6
[Contact and dialogue between drug companies and the global regulatory authorities throughout research and development phase].[制药公司与全球监管机构在整个研发阶段的接触与对话]
Ugeskr Laeger. 2003 Apr 14;165(16):1649-52.
7
Chronological changes in baseline disease activity of patients with rheumatoid arthritis who received biologic DMARDs between 2003 and 2012.2003年至2012年间接受生物性改善病情抗风湿药治疗的类风湿关节炎患者基线疾病活动度的时间变化。
Mod Rheumatol. 2015 May;25(3):350-7. doi: 10.3109/14397595.2014.958274. Epub 2015 Jan 25.
8
Timing of Pediatric Drug Approval and Clinical Evidence Submitted to Regulatory Authorities: International Comparison Among Japan, the United States, and the European Union.儿科药物批准时间与向监管机构提交的临床证据：日本、美国和欧盟的国际比较。
Clin Pharmacol Ther. 2020 Nov;108(5):985-994. doi: 10.1002/cpt.1757. Epub 2020 Jan 25.
9
Quality, safety and efficacy of follow-on biologics in Japan.日本生物类似药的质量、安全性和有效性。
Biologicals. 2011 Sep;39(5):328-32. doi: 10.1016/j.biologicals.2011.06.015. Epub 2011 Sep 3.
10
Electrophysiology devices and the regulatory approval process within the U.S. FDA and abroad.美国食品药品监督管理局（FDA）及国外的电生理设备与监管审批流程。
J Interv Card Electrophysiol. 2019 Nov;56(2):173-182. doi: 10.1007/s10840-019-00607-x. Epub 2019 Aug 16.

引用本文的文献

1
Targeting the CD47-SIRPalpha checkpoint in multiple myeloma.靶向多发性骨髓瘤中的CD47-SIRPα检查点
Discov Oncol. 2025 Aug 25;16(1):1616. doi: 10.1007/s12672-025-03312-6.
2
High-affinity transferrin receptor binding improves brain delivery of bispecific antibodies at tracer dose.高亲和力转铁蛋白受体结合可提高示踪剂量双特异性抗体的脑内递送。
Fluids Barriers CNS. 2025 Aug 21;22(1):86. doi: 10.1186/s12987-025-00693-2.
3
New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies.
嵌合抗原受体T细胞血液学毒性的新见解：表现、机制及有效管理策略
Exp Hematol Oncol. 2024 Nov 9;13(1):110. doi: 10.1186/s40164-024-00573-9.
4
Health-related quality of life dynamics: modeling insights from immunotherapy.健康相关生活质量动态：来自免疫疗法的建模见解
Qual Life Res. 2025 Jan;34(1):273-286. doi: 10.1007/s11136-024-03810-0. Epub 2024 Oct 30.
5
Application of In vitro transcytosis models to brain targeted biologics.体外转胞模型在脑靶向生物制剂中的应用。
PLoS One. 2023 Aug 23;18(8):e0289970. doi: 10.1371/journal.pone.0289970. eCollection 2023.
6
Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer.嵌合抗原受体 T 细胞疗法在结直肠癌和浸润性乳腺癌中的最新临床观点和挑战。
Arch Immunol Ther Exp (Warsz). 2023 Aug 11;71(1):19. doi: 10.1007/s00005-023-00684-x.
7
Blood-Brain Barrier (BBB)-Crossing Strategies for Improved Treatment of CNS Disorders.血脑屏障（BBB）穿越策略，改善中枢神经系统疾病的治疗。
Handb Exp Pharmacol. 2024;284:213-230. doi: 10.1007/164_2023_689.
8
Targeting neuronal lysosomal dysfunction caused by β-glucocerebrosidase deficiency with an enzyme-based brain shuttle construct.针对β-葡糖脑苷脂酶缺乏引起的神经元溶酶体功能障碍，采用基于酶的脑穿梭构建体。
Nat Commun. 2023 Apr 12;14(1):2057. doi: 10.1038/s41467-023-37632-4.
9
CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a sweet success?针对肿瘤特异性抗原糖型的嵌合抗原受体 T 细胞：低聚糖抗原能保证成功吗？
Front Med. 2022 Jun;16(3):322-338. doi: 10.1007/s11684-021-0901-2. Epub 2022 Jun 10.
10
Optimal model establishment of whole-process management data for CAR-T therapy in China-how should this be done?中国CAR-T治疗全过程管理数据的最佳模型建立——该如何进行？
Cell Mol Immunol. 2022 Jan;19(1):122-124. doi: 10.1038/s41423-021-00789-3. Epub 2021 Oct 25.